Christopher Desmond to Tumor Necrosis Factor-alpha
                            
                            
                                This is a "connection" page, showing publications Christopher Desmond has written about Tumor Necrosis Factor-alpha.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            0,158
         
        
        
     
 
    
        
        - 
            Immunomodulator use does not prevent first loss of response to anti-tumour necrosis factor alpha therapy in inflammatory bowel disease: long-term outcomes in a real-world cohort. Intern Med J. 2019 06; 49(6):753-760.
            
            
                Score: 0,158